Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STAR-TREC: Organ preservation versus total mesorectal excision in early rectal cancer
2016-000862-49Phase 2Active
- Sponsor
- University of Birmingham
- Start
- May 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of capecitabine in rectal adenocarcinoma and rectal cancer (3 arms), sponsored by University of Birmingham. Primary endpoint: Feasibility of recruitment. Started May 2016; status: active.
02
Drugs
capecitabine
03
Conditions
rectal adenocarcinomarectal cancer
Beyond the preview
Go deeper on 2016-000862-49.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000862-49.